Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies.
Chagas disease
Trypanosoma cruzi
benznidazole
biopharmaceutical study
nanoparticles
nanostructured lipid carriers
physicochemical characterization
Journal
Beilstein journal of nanotechnology
ISSN: 2190-4286
Titre abrégé: Beilstein J Nanotechnol
Pays: Germany
ID NLM: 101551563
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
04
2023
accepted:
06
07
2023
medline:
3
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Chagas disease is a neglected endemic disease prevalent in Latin American countries, affecting around 8 million people. The first-line treatment, benznidazole (BNZ), is effective in the acute stage of the disease but has limited efficacy in the chronic stage, possibly because current treatment regimens do not eradicate transiently dormant
Identifiants
pubmed: 37533841
doi: 10.3762/bjnano.14.66
pmc: PMC10390827
doi:
Types de publication
Journal Article
Langues
eng
Pagination
804-818Informations de copyright
Copyright © 2023, Muraca et al.
Références
Nano Lett. 2008 Aug;8(8):2180-7
pubmed: 18605701
AAPS J. 2010 Sep;12(3):263-71
pubmed: 20373062
Rev Inst Med Trop Sao Paulo. 2020;62:e52
pubmed: 32725057
J Antimicrob Chemother. 1993 Jan;31(1):9-20
pubmed: 8444678
Bioorg Med Chem Lett. 2001 Feb 26;11(4):479-82
pubmed: 11229752
Int J Pharm. 2002 Aug 21;242(1-2):121-8
pubmed: 12176234
Front Chem. 2020 Nov 26;8:601151
pubmed: 33324615
Science. 1991 Jun 28;252(5014):1851-4
pubmed: 1829548
Acta Trop. 2019 Oct;198:105080
pubmed: 31299283
Acta Trop. 2015 Dec;152:8-16
pubmed: 26272680
Nanomaterials (Basel). 2022 Jan 13;12(2):
pubmed: 35055267
Circulation. 2018 Sep 18;138(12):e169-e209
pubmed: 30354432
N Engl J Med. 2015 Oct;373(14):1295-306
pubmed: 26323937
PLoS Negl Trop Dis. 2012;6(12):e1951
pubmed: 23272261
Nat Rev Microbiol. 2007 Apr;5(4):287-97
pubmed: 17363967
Int J Pharm. 2019 Jan 30;555:36-48
pubmed: 30448310
Front Cell Dev Biol. 2021 Nov 01;9:720536
pubmed: 34790656
Clin Res Cardiol. 2014 Jan;103(1):1-10
pubmed: 23989652
Lancet. 1996 Nov 23;348(9039):1407-13
pubmed: 8937280
Colloids Surf B Biointerfaces. 2016 Jul 1;143:168-176
pubmed: 27003467
Biomaterials. 2015 May;51:91-107
pubmed: 25771001
Lancet Infect Dis. 2001 Sep;1(2):92-100
pubmed: 11871482
Carbohydr Polym. 2012 Jul 1;89(3):1003-7
pubmed: 24750892
Colloids Surf B Biointerfaces. 2022 Sep;217:112678
pubmed: 35816885
J Microencapsul. 2008 Mar;25(2):111-20
pubmed: 18246489
Pathogens. 2019 Oct 19;8(4):
pubmed: 31635071
Am J Trop Med Hyg. 2017 Nov;97(5):1469-1476
pubmed: 29016287
Int J Nanomedicine. 2015 Apr 07;10:2805-14
pubmed: 25897224
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9735-9
pubmed: 7937882
Int J Nanomedicine. 2016 Jul 12;11:3167-78
pubmed: 27471384
Biomaterials. 2003 May;24(10):1781-5
pubmed: 12593960
Colloids Surf B Biointerfaces. 2018 Jul 1;167:73-81
pubmed: 29627680
PLoS One. 2017 Sep 26;12(9):e0185033
pubmed: 28949997
Front Mol Biosci. 2020 Oct 30;7:587997
pubmed: 33195435
AAPS PharmSciTech. 2021 Sep 29;22(7):240
pubmed: 34590195
Int J Pharm. 2000 Apr 20;199(2):167-77
pubmed: 10802410
Acta Trop. 2020 May;205:105361
pubmed: 32006523
Chem Res Toxicol. 2015 Mar 16;28(3):501-9
pubmed: 25602487
Pharm Nanotechnol. 2018;6(4):253-263
pubmed: 30574859
J Am Chem Soc. 2010 Apr 7;132(13):4834-42
pubmed: 20230032
Mem Inst Oswaldo Cruz. 1983 Oct-Dec;78(4):437-42
pubmed: 6443630
Nanomedicine (Lond). 2015 Feb;10(3):465-81
pubmed: 25707979
Front Chem. 2022 Aug 17;10:908386
pubmed: 36059881
Expert Rev Anti Infect Ther. 2021 May;19(5):547-556
pubmed: 33043726